New product: Entyvio (vedolizumab) 108 mg solution for injection in pre-filled syringe

This new formulation is a subcutaneous injection, licensed for the treatment of ulcerative colitis and Crohn's disease. Recommended dose regimen as a maintenance treatment, following at least 2 IV infusions, is 108 mg administered by subcutaneous injection once every 2 weeks.


electronic Medicines compendium